JP2019508408A5 - - Google Patents

Download PDF

Info

Publication number
JP2019508408A5
JP2019508408A5 JP2018541252A JP2018541252A JP2019508408A5 JP 2019508408 A5 JP2019508408 A5 JP 2019508408A5 JP 2018541252 A JP2018541252 A JP 2018541252A JP 2018541252 A JP2018541252 A JP 2018541252A JP 2019508408 A5 JP2019508408 A5 JP 2019508408A5
Authority
JP
Japan
Prior art keywords
therapeutic
poly
ethylene
antibody
nanoparticle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2018541252A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019508408A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2017/050762 external-priority patent/WO2017137953A1/en
Publication of JP2019508408A publication Critical patent/JP2019508408A/ja
Publication of JP2019508408A5 publication Critical patent/JP2019508408A5/ja
Withdrawn legal-status Critical Current

Links

JP2018541252A 2016-02-10 2017-02-10 治療剤を含む治療用ナノ粒子ならびにそれを作製および使用する方法 Withdrawn JP2019508408A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662293617P 2016-02-10 2016-02-10
US62/293,617 2016-02-10
PCT/IB2017/050762 WO2017137953A1 (en) 2016-02-10 2017-02-10 Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same

Publications (2)

Publication Number Publication Date
JP2019508408A JP2019508408A (ja) 2019-03-28
JP2019508408A5 true JP2019508408A5 (enExample) 2020-03-19

Family

ID=58159116

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018541252A Withdrawn JP2019508408A (ja) 2016-02-10 2017-02-10 治療剤を含む治療用ナノ粒子ならびにそれを作製および使用する方法

Country Status (11)

Country Link
US (1) US20210188979A1 (enExample)
EP (1) EP3413918A1 (enExample)
JP (1) JP2019508408A (enExample)
KR (1) KR20180101462A (enExample)
CN (1) CN108778340A (enExample)
AU (1) AU2017218767A1 (enExample)
BR (1) BR112018014998A2 (enExample)
CA (1) CA3013880A1 (enExample)
MX (1) MX2018009723A (enExample)
RU (1) RU2018129118A (enExample)
WO (1) WO2017137953A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019055234A1 (en) * 2017-09-13 2019-03-21 Massachusetts Institute Of Technology LOCAL ADMINISTRATION OF TARGETED THERAPEUTIC AGENTS DIRECTED BY GENOTYPE
WO2020030954A1 (en) * 2018-08-09 2020-02-13 Integrative Medicine Clinic, Sia Theranostics-like protein sanps conjugated to integrin and pmsa targeting peptides and therapy of prostate cancer
US20230086800A1 (en) * 2020-03-06 2023-03-23 The Board Of Trustees Of The Leland Stanford Junior University Antibody fragments conjugated to peg-plga nanoparticles improve immunotherapy against cancer cells
GB202103785D0 (en) * 2021-03-18 2021-05-05 UCB Biopharma SRL Formulations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US20050042298A1 (en) * 2003-08-20 2005-02-24 Pardridge William M. Immunonanoparticles
JP2012501965A (ja) * 2008-06-16 2012-01-26 バインド バイオサイエンシズ インコーポレイテッド 薬剤を装填したポリマーナノ粒子及びその製造方法と使用方法
WO2011072218A2 (en) * 2009-12-11 2011-06-16 Bind Biosciences Stable formulations for lyophilizing therapeutic particles
AU2015279738A1 (en) * 2014-06-25 2016-12-22 Selecta Biosciences, Inc. Methods and compositions for treatment with synthetic nanocarriers and immune checkpoint inhibitors

Similar Documents

Publication Publication Date Title
US11931465B2 (en) Functionalized Prussian blue nanoparticles, combination Prussian blue nanoparticle-based nano-immunotherapy and applications thereof
Musetti et al. Nanoparticle-mediated remodeling of the tumor microenvironment to enhance immunotherapy
JP2019508408A5 (enExample)
Nuhn et al. pH-degradable imidazoquinoline-ligated nanogels for lymph node-focused immune activation
Kaur et al. Surfactant-based drug delivery systems for treating drug-resistant lung cancer
WO2011079279A3 (en) Nanoconjugates and nanoconjugate formulations
Welte et al. Interleukin‐17 could promote breast cancer progression at several stages of the disease
Park et al. Immunomodulatory magnetic microspheres for augmenting tumor-specific infiltration of natural killer (NK) cells
JP2009527566A5 (enExample)
HRP20231504T1 (hr) Polisaharidi kapsule iz bakterije streptococcus pneumoniae i njihovi konjugati
JP2017036323A5 (enExample)
JP2017523781A5 (enExample)
JP2018503668A5 (enExample)
FR2919804B1 (fr) Composition et vaccin therapeutique anti-tumoral
EA200901451A1 (ru) Самособирающиеся амфифильные полимеры в качестве противоопухолевых средств
WO2016004048A3 (en) Targeted conjugates and particles and formulations thereof
WO2018134691A3 (en) Cell surface conjugates and related cell compositions and methods
JP2017535581A5 (enExample)
WO2015027054A3 (en) Telodendrimers and nanocarriers and methods of using same
JP2016529286A5 (enExample)
JP2007524613A5 (enExample)
WO2018094309A3 (en) Fractal combination therapy
JP2019509715A5 (enExample)
RU2018129118A (ru) Терапевтические наночастицы, содержащие терапевтический агент, и способы их получения и применения
Rofeal et al. Dual therapeutic targeting of lung infection and carcinoma using lactoferrin-based green nanomedicine